| Lopinavir and Ritonavir | Abbvie | ||
| 200mg; 50mg,100mg; 25mg ,Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| Indicated in combination with other antiretroviral agents for the treatment of HIV1 infection in adults and pediatric patients | |||
|
Yes
| |||
| Kaletra | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 |
|---|---|---|---|---|---|---|---|---|---|
| ***** (******) | ******* | **** *** | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ****** | ******* | ******* | **** *** | ******* | ******* | ******* | ******* | ******* | ******* |
| ********* | ******* | **** *** | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** (******) | *** \ ** | ****, **** | ******* | ******** | *** ****** ******* |
| ****** | ** \ ** | ***** *, **** | ******* | ******** | ******** ** *** *, **** |
| ********* | ** \ ** | **** **, **** | ******* | ********* ******** | ****** **** ******** |
| Lopinavir and Ritonavir | Abbott | ||
| 80mg/20mg per ml; oral solution |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older. | |||
|
Yes
| |||
| Kaletra | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| ***** | **** *** | **** *** | **** *** | **** *** | **** *** | **** *** | **** *** | **** *** | **** *** | **** *** | ** *** ****** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ ** | ** | *** ********* | ******** | ******** ** *** **, **** |
| ***** | ** \ ** | ** | *** ********* | ********* ******** | ***** *** **, **** |
Download ParaIV Report